A Phase 4 interventional study of Efinaconazole in Onychomycosis, sponsored by Bausch Health Americas, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 6 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-01.
Sponsored by Bausch Health Americas, Inc. · Phase 4, Interventional, and Treatment
Safety and Pharmacokinetics (PK) of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
This is an open label, single-arm study designed to evaluate the safety and PK of a once daily topical application of efinaconazole in the treatment of pediatric subjects with mild to severe onychomycosis of the toenails.
147 studies on the registry are indexed under Onychomycosis; 13 are open to participants now.
This study's enrollment of 62 is above the median of 56 across 134 interventional studies indexed under Onychomycosis.
Browse Onychomycosis studies →Bausch Health Americas, Inc. is the lead sponsor of 209 studies on the registry; 9 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 16 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Efinaconazole
Drug: Efinaconazole
Solution
Percentage of Participants With at Least One Adverse Event
Time frame: 48 weeks
| Milestone | Efinaconazole |
|---|---|
| Started | 62 |
| Completed | 50 |
| Not completed | 12 |
| Participants | Efinaconazole |
|---|---|
| Percentage of Participants With at Least One Adverse Event | 39 |
Collected over 48 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efinaconazole | 0/60 (0%) | 2/60 (3.3%) | 20/60 (33.3%) |
| Event | Efinaconazole |
|---|---|
| PneumoniaInfections and infestations | 1/60 |
| Ankle fractureInjury, poisoning and procedural complications | 1/60 |
| Event | Efinaconazole |
|---|---|
| NasopharyngitisInfections and infestations | 18/60 |
| HeadacheNervous system disorders | 6/60 |
| InfluenzaInfections and infestations | 5/60 |
| ContusionInjury, poisoning and procedural complications | 4/60 |
| Nail injuryInjury, poisoning and procedural complications | 4/60 |
| Ingrowing nailSkin and subcutaneous tissue disorders | 4/60 |
| Tinea pedisInfections and infestations | 4/60 |
| Food poisoningGastrointestinal disorders | 3/60 |
Of the 62 participants who were enrolled in the study, 2 did not apply study drug and were excluded from all analysis populations.
| Age, Continuous(years) | Efinaconazole |
|---|---|
| Mean | 13.4 ± 2.29 |
| Sex: Female, Male(Participants) | Efinaconazole |
|---|---|
| Female | 20 |
| Male | 40 |
| Race (NIH/OMB)(Participants) | Efinaconazole |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 53 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Target Great Tonail(Participants) | Efinaconazole |
|---|---|
| Left | 32 |
| Right | 28 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bausch Health Americas, Inc.